本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
DONGGUAN, China and PLANO, Texas, March 31, 2025 /PRNewswire/ -- Dogness (International) Corporation ("Dogness" or the "Company") (NASDAQ: DOGZ), a developer and manufacturer of a comprehensive line of Dogness-branded, OEM and private label pet products, today announced its financial results for the six months ended December 31, 2024. Mr. Silong Chen, the CEO of the Company, commented: "We delivered robust financial results for the half year ended December 2024, marked by strong revenue growth, increased operational efficiency, and progress toward profitability. Our revenue reached $12.1 million for the six months ended December 2024, an 81.1% increase from the same period in 2023, driven by high demand across all product categories and regions. Meanwhile, our ongoing efforts on cost management and economies of scale have significantly improved operating results. "Looking ahead, Dogness aims to accelerate product innovation, expand its global market presence and drive cost efficiencies. The Company plans to acquire smaller pet product manufacturers in China to strengthen supply chain control and operational efficiencies, thereby increasing market share. With a focus on developing sustainable, high-tech pet products and leveraging strategic partnerships, we anticipate further revenue growth, improved profitability and increased shareholder value." Financial Results for the Half Year Ended December 31, 2024 Revenues increased by approximately $5.4 million, or 81.1%, from about $6.7 million for the year ended December 31, 2023 to approximately $12.1 million for the six months ended December 31, 2024. The increase in revenue was primarily attributable to the strong sales performance in both China's domestic market and international markets, driven by higher demand from existing customers and new customer. The following table breaks down Dogness' revenue by product and service type for the six months ended December 31, 2024 and 2023: For the six months ended December 31, 2024 2023 Products and services category Revenue Revenue Variance % Products Traditional pet products $ 4,660,824 $ 3,601,676 29.4 % Intelligent pet 4,546,642 2,234,220 103.5 % Climbing hooks and others 2,878,245 761,742 277.9 % Total revenue fromproducts 12,085,711 6,597,638 83.2 % Services Dyeing services - 77,049 (100.0) % Total revenue fromservices - 77,049 (100.0) % Total $ 12,085,711 $ 6,674,687 81.1 % ─ Traditional pet products Revenue from traditional pet products increased by approximately $1.1 million, or 29.4%, from approximately $3.6 million for the six months ended December 31, 2023 to approximately $4.7 million for the six months ended December 31, 2024. This growth was driven both higher sales volume and increased average selling prices. Of the revenue growth, $1.0 million came from international sales and $0.1 million from the domestic Chinese market, primarily due to expanded order volumes from customers. ─ Intelligent pet products Revenue from intelligent pet products grew by approximately $2.3 million, or 103.5%, from around $2.2 million for the six months ended December 31, 2023, to roughly $4.5 million for the same period in 2024, mainly due to increased sales volume. The revenue increase included $1.2 million from international customers and $1.1 million from domestic Chinese customers, primarily from new and existing orders. ─ Climbing hooks and others Revenue from climbing hooks and other products increased by about $2.1 million, or 277.9%, from roughly $0.8 million for the six months ended December 31, 2023, to about $2.9 million for the same period in 2024. This increase was influenced by higher sales volume and prices. International sales contributed $1.3 million to the revenue increase, while domestic sales accounted for $0.8 million, driven by higher orders. ─ Dyeing service For the six months ended December 31, 2024 and 2023, the Company earned approximately $Nil and $0.1 million, respectively, for dyeing services. ─ International vs. Domestic sales Total international sales rose by about $3.4 million, or 75.9%, from approximately $4.5 million for the six months ended December 31, 2023, to about $8.0 million during the same period in 2024, driven by increased orders across all product types. Domestic sales also saw a significant increase of about $2.0 million, or 92.0%, from around $2.1 million in 2023 to approximately $4.1 million in 2024. In the domestic market, sales of traditional pet products, intelligent pet products, and climbing hooks increased by 16.2%, 109.2%, and 198.5%, respectively, compared to the previous year. Cost of revenues increased by $3.3 million, or 61.6%, from approximately $5.4 million for the six months ended December 31, 2023, to approximately $8.7 million for the six months ended December 31, 2024, due to a significant increase in sales volume. As a percentage of revenues, the cost of goods sold decreased by approximately 8.7 percentage points to 71.7% for the six months ended December 31, 2024, compared to 80.4% for the six months ended December 31, 2023. Gross profit rose by approximately $2.1 million, or 160.7%, from about $1.3 million for the six months ended December 31, 2023, to around $3.4 million for the same period in 2024. This increase resulted from higher sales volume and average selling prices. The overall gross profit margin improved to 28.3%, up 8.7 percentage points from 19.6% in the previous period. Total operating expenses increased by approximately $0.7 million or 14.6%, to about $5.6 million for the six months ended December 31, 2024, compared to around $4.9 million for the same period in 2023. ─ Selling expenses Selling expenses increased by about $0.1 million, or 18.0%, from approximately $0.5 million for the six months ended December 31, 2023, to approximately $0.6 million for the six months ended December 31, 2024. This rise was driven by an increase in marketing research activities. Selling expenses accounted for 5.2% of total revenues in 2024, compared to 7.9% in 2023. ─ General and Administrative Expenses General and administrative expenses rose by approximately $0.4 million, or 11.3%, from about $3.9 million for the six months ended December 31, 2023, to roughly $4.3 million for the same period in 2024. This increase was primarily attributable to office decoration costs at our new Dongguan facility. As a percentage of sales, these expenses decreased to 35.7% in 2024 from 58.0% in 2023. ─ Research and Development Expenses Research and development expenses increased by $0.2 million, or 37.0%, from approximately $0.5 million for the six months ended December 31, 2023, to about $0.7 million for the same period in 2024. These expenses were 5.5% of total revenues in 2024, down from 7.3% in 2023. We anticipate continued growth in research and development as we expand our efforts to use environmentally friendly materials and develop new high-tech products to meet customer demand. Net loss decreased by approximately $1.4 million, or 43.2%, from about $3.2 million for the six months ended December 31, 2023, to approximately $1.8 million for the six months ended December 31, 2024, as a result of the foregoing. About Dogness Dogness (International) Corporation was founded in 2003 from the belief that dogs and cats are important, well-loved family members. Through its smart products, hygiene products, health and wellness products, and leash products, Dogness' technology simplifies pet lifestyles and enhances the relationship between pets and pet caregivers. The Company ensures industry-leading quality through its fully integrated vertical supply chain and world-class research and development capabilities, which has resulted in over 200 patents and patents pending. Dogness products reach families worldwide through global chain stores and distributors. For more information, please visit: ir.dogness.com. Forward Looking Statements No statement made in this press release should be interpreted as an offer to purchase or sell any security. Such an offer can only be made in accordance with the Securities Act of 1933, as amended, and applicable state securities laws. Certain statements in this press release concerning our future growth prospects are forward-looking statements regarding our future business expectations intended to qualify for the "safe harbor" under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding, our ability to raise capital on any particular terms, fulfillment of customer orders, fluctuations in earnings, fluctuations in foreign exchange rates, trade policies affecting our business including tariffs on our products, our ability to manage growth, our ability to realize revenue from expanded operation and acquired assets in China and the U.S., our ability to attract and retain highly skilled professionals, client concentration, industry segment concentration, reduced demand for technology in our key focus areas, our ability to successfully complete and integrate potential acquisitions, and unauthorized use of our intellectual property and general economic conditions affecting our industry. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings. These filings are available at www.sec.gov. Dogness may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company's filings with the Securities and Exchange Commission and our reports to shareholders. In addition, please note that any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of the date of this press release. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law. For investor and media inquiries, please contact:Wealth Financial Services LLCConnie Kang, PartnerEmail: ckang@wealthfsllc.com Tel: +86 1381 185 7742 (CN) DOGNESS (INTERNATIONAL) CORPORATION CONSOLIDATED BALANCE SHEETS (All amounts in USD) (Unaudited) As of December 31, As of June 30, 2024 2024 ASSETS CURRENT ASSETS Cash and cash equivalents $ 6,057,762 $ 6,956,434 Accounts receivable from third-party customers, net 3,298,433 2,269,341 Accounts receivable from related party 311,713 582,182 Inventories, net 3,228,661 3,119,827 Due from related party 101,491 97,037 Prepayments and other current assets 3,374,352 3,328,189 Advances to supplier- related party - 50,908 Total current assets 16,372,412 16,403,918 NON-CURRENT ASSETS Property, plant and equipment, net 60,593,968 61,303,327 Operating lease right-of-use lease assets 15,679,000 16,325,988 Intangible assets, net 1,744,340 1,780,856 Long-term investments in equity investees 1,507,000 1,513,600 Deferred tax assets 1,972,480 1,873,140 Total non-current assets 81,496,788 82,796,911 TOTAL ASSETS $ 97,869,200 $ 99,200,829 LIABILITIES AND EQUITY CURRENT LIABILITIES Short-term bank loans $ 890,500 $ 894,400 Current portion of long-term bank loans 900,936 759,339 Accounts payable 2,264,565 1,286,981 Accounts payable - related party 12,913 - Due to related parties 71,994 518,003 Advances from customers 224,676 264,832 Taxes payable 1,029,282 1,007,482 Accrued expenses and other current liabilities 1,504,502 1,452,225 Operating lease liabilities, current 2,279,655 2,352,482 Total current liabilities 9,179,023 8,535,744 NON-CURRENT LIABILITIES Long-term bank loans 2,845,274 3,315,715 Operating lease liabilities, non-current 11,150,861 10,938,477 Total non-current liabilities 13,996,135 14,254,192 TOTAL LIABILITIES 23,175,158 22,789,936 Commitments and Contingencies (Note 6) EQUITY Class A Common shares, no par value, unlimited sharesauthorized; 3,661,658 issued and outstanding as of December 31, 2024 and June 30, 2024 92,403,766 92,004,296 Class B Common shares, no par value, unlimited shares authorized; 9,069,000 issued and outstanding as of December 31, 2024 and June 30, 2024 18,138 18,138 Statutory reserve 291,443 291,443 Accumulated deficit (7,207,552) (5,391,709) Accumulated other comprehensive loss (10,811,795) (10,511,317) Equity attributable to owners of the Company 74,694,000 76,410,851 Non-controlling interest 42 42 Total equity 74,694,042 76,410,893 TOTAL LIABILITIES AND EQUITY $ 97,869,200 $ 99,200,829 DOGNESS (INTERNATIONAL) CORPORATION STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (All amounts in USD) (Unaudited) For the Six Months Ended December 31, 2024 2023 Revenues–third party customers $ 12,085,711 $ 6,573,379 Revenues – related parties - 101,308 Total Revenues 12,085,711 6,674,687 Cost of revenues – third party customers (8,668,552) (5,280,923) Cost of revenues – related parties - (82,835) Total Cost of revenues (8,668,552) (5,363,758) Gross Profit 3,417,159 1,310,929 Operating expenses: Selling expenses 624,410 529,021 General and administrative expenses 4,312,486 3,873,442 Research and development expenses 665,494 485,849 Total operating expenses 5,602,390 4,888,312 Loss from operations (2,185,231) (3,577,383) Other income (expense): Interest income (expense), net 6,884 (113,690) Foreign exchange transaction gain 114,443 32,469 Other income, net 41,357 80,891 Rental income from related parties, net 107,737 148,406 Total other income, net 270,421 148,076 Loss before income taxes (1,914,810) (3,429,307) Income taxes benefit (98,967) (231,756) Net loss (1,815,843) (3,197,551) Less: net loss attributable to non-controlling interest - (934) Net loss attributable to Dogness (International) Corporation (1,815,843) (3,196,617) Other comprehensive loss Foreign currency translation adjustments (300,478) 1,666,560 Comprehensive loss (2,116,321) (1,530,991) Less: comprehensive loss attributable to non-controllinginterest - (931) Comprehensive loss attributable to Dogness(International) Corporation $ (2,116,321) $ (1,530,060) Loss Per share Basic $ (0.14) $ (0.30) Diluted $ (0.14) $ (0.30) Weighted Average Shares Outstanding Basic 12,755,658 10,622,663 Diluted 12,755,658 10,622,663 DOGNESS (INTERNATIONAL) CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS (All amounts in USD) (Unaudited) For the Six Months Ended December 31, 2024 2023 Cash flows from operating activities: Net loss $ (1,815,843) $ (3,197,551) Adjustments to reconcile loss income to net cash provided by (used in) operating activities: Depreciation and amortization 1,395,756 1,414,937 Share-based compensation for services 399,470 399,470 Loss (gain) from disposal of property, plant and equipment 176,347 (9,845) Change in credit losses (232,600) 111,105 Deferred tax benefit (108,490) (275,121) Amortization of right-of-use lease assets 585,466 591,705 Warrants modification - 239,308 Changes in operating assets and liabilities: Accounts receivable (824,001) (682,445) Accounts receivable-related party 272,429 177,374 Inventories (121,257) (359,976) Prepayments and other current assets (61,720) (1,080,158) Advances to supplier-related party 51,537 126,527 Accounts payables 999,703 425,101 Accounts payables-related party 13,130 - Accrued expenses and other current liabilities 24,691 16,516 Advance from customers (39,639) 104,887 Operating lease liabilities 200,827 188,379 Taxes payable 26,242 159,612 Net cash provided by (used in) operating activities 942,048 (1,650,175) Cash flows from investing activities: Purchase of property, plant and equipment (1,050,711) (294,828) Proceeds from disposition of property, plant and equipment 787 56,000 Net cash used in investing activities (1,049,924) (238,828) Cash flows from financing activities: Net proceeds from exercise of warrants - 15,101 Reverse split shares - (810) Proceeds from short-term bank loans 696,500 691,000 Repayment of short-term bank loans (696,500) (885,800) Proceeds from long-term bank loans - 2,625,800 Repayment of long-term bank loans (316,297) (2,793,472) (Repayment of) proceeds from related-party loans (456,160) 6,498 Net cash used in financing activities (772,457) (341,683) Effect of exchange rate changes on cash and restricted cash (18,339) 226,388 Net decrease in cash and cash equivalents (898,672) (2,004,298) Cash and cash equivalents, beginning of period 6,956,434 4,483,308 Cash and cash equivalents, end of period $ 6,057,762 $ 2,479,010 SUPPLEMENTAL DISCLOSURES OF CASH FLOWINFORMATION: Cash paid for interest $ 115,430 $ 154,884 Non-Cash Investing Activities Liabilities incurred (settled) for purchase of property andequipment $ 34,909 $ (40,251) Prepaid share-based compensation for services $ - $ (223,000)
LIBOURNE, France, March 31, 2025 /PRNewswire/ -- Ceva Animal Health (Ceva), the world's fifth-largest animal health company, announces the restructuring of its capital. All investors, whether "Friends of Ceva" or pure investors led by Temasek, have renewed their investment, demonstrating their confidence in the company's ability to continue its sustained growth. Ceva's management, led by Dr. Marc Prikazsky, has reinforced its participation and still retains the majority of voting rights, reaffirming the company's commitment to remaining independent. It is supported by a core group of long-term investors, known as "Friends of Ceva" ensuring a stable and committed shareholding structure for the group's development. With 7,000 employees, Ceva is a global leader in animal health, particularly in vaccination. Operating directly in 47 countries, the company delivers its products, services and equipment's worldwide to veterinarians, livestock professionals, and pet owners. To support innovation in animal health, the Bettencourt-Meyers and Mérieux, have increased their stake through the investment holding Téthys Invest and Mérieux Institute that joined forces with investment fund Mérieux Equity Partners. Canadian pension investor PSP Investments, a long-term investor in Ceva, has also significantly increased its ownership in the group. Other companies participating in the "Friends of Ceva" include Sofiprotéol, the investment branch of the French group Avril, the Japanese company Mitsui & Co., as well as some local investment funds and the Klocke family. The long-standing minority investors have renewed their commitment, demonstrating their confidence in Ceva's future. Leading this group of partners is the Singapore-based global investment firm Temasek, joined by French investors EMZ and Sagard, Asia-based HOPU Investments, and U.S.-based Continental Grain Company. This sixth funding round also welcomes the addition of the French investment fund ARCHIMED, led by veterinarian Dr. Denis Ribon. Specializing in the healthcare sector, ARCHIMED focuses on supporting companies in expanding internationally and accelerating their research programs. Since its founding in 1999, Ceva has grown its revenue fourteenfold, reaching €1.77 billion last year. Driven by innovation and deeply committed to preventive medicine, Ceva was the first veterinary company to develop and commercialize a cutting-edge nucleotide vaccine and invest in gene therapy for companion animals. Aware of its responsibility in addressing major global challenges, Ceva is strongly committed to reducing its environmental impact and promoting the preservation of animal biodiversity. "I am delighted to see that in this new round of financing, the management's participation, supported by the 'Friends of Ceva', is being strengthened alongside our historic financial investors and new entrants. Ceva plays a major role in animal health, particularly in the fight against emerging diseases, sometimes zoonotic, and in the treatment of chronic diseases affecting our loyal four-legged companions. At Ceva, we are convinced that we must continue to create bridges between different health sectors to protect the health of ecosystems and humans as well as global food security," said Dr. Marc Prikazsky, Chairman and CEO of Ceva Animal Health. Ceva would like to thank its advisors, Lazard, Rothschild, Weil, and Callisto, and their teams for their support. About Ceva Animal Health Ceva Animal Health (Ceva) is the 5th global animal health company, led by experienced veterinarians, whose mission is to provide innovative health solutions for all animals to ensure the highest level of care and well-being. Our portfolio includes preventive medicine such as vaccines and animal welfare products, pharmaceutical solutions for farm and companion animals, as well as equipment and services to provide the best experience for our customers. With more than 7,000 employees located in 47 countries, Ceva strives daily to bring to life its vision as a One Health company: "Together, beyond animal health". 2024 turnover: €1.77 billion Contact: Emilie Barrail, Head of external communication, emilie.barrail@ceva.com
ORLANDO, Fla., March 25, 2025 /PRNewswire/ -- Cheerble, a leading innovator in the pet technology industry, is excited to announce its participation at Global Pet Expo 2025, marking its third consecutive year at the premier industry event. The event will provide as the platform for unveiling Cheerble's latest innovations, including its Wicked Series of interactive pet toys and its revolutionary pet care solution. The Wicked Series of interactive pet toys has gained significant recognition for its blend of innovative technology and pet enrichment. Among the latest releases is the Wicked Ball Air, an interactive dog ball that has rapidly risen to the top 3 on Amazon's Best Seller Rank (BSR) in its category, becoming the fastest-growing product in just three months. Featuring advanced E-TPU material, the Wicked Ball Air delivers dynamic play that fosters both physical and mental stimulation, enriching dogs' playtime like never before. Also featured is the Wicked Ball M3, a next-generation interactive cat toy designed to elevate cats' play. With enhanced features tailored to cater to different energy levels, the Wicked Ball M3 provides an engaging and interactive experience, appealing to pet parents seeking innovative ways to entertain and care for their feline companions. In addition to its interactive pet toys, Cheerble will spotlight its Cheerble Pet Fountain Elfin E1+, known for its pumpless design that sets a new standard in pet water fountain sections. This design minimizes maintenance while ensuring a fresh, quiet water flow for pets, aligning with Cheerble's mission to solve real challenges faced by pet parents while elevating pet care aesthetics. "Global Pet Expo 2025 is the ideal platform for Cheerble to showcase our continued innovation in both interactive pet toys and pet care solutions," said Seven Xie, CEO at Cheerble. "We're thrilled to introduce pet parents and retailers to our growing portfolio of products. Each of these products represents our commitment to making life better for pets and their families." As Cheerble celebrates its third year at Global Pet Expo, it continues to strengthen its position as a leading brand in the pet industry. Attendees are invited to visit Booth 4787 to explore Cheerble's latest products and experience firsthand how the brand is revolutionizing the pet care and toy categories. For more information about Cheerble and its products, visit www.cheerble.com. About CheerbleCheerble is a pioneering pet technology brand dedicated to designing innovative, interactive pet products that enrich the lives of pets and their parents. From smart toys to advanced pet care solutions, Cheerble continues to set the standard in the pet industry. Email: press@cheerble.com Instagram: https://www.instagram.com/cheerble_global/Facebook: https://www.facebook.com/CheerbleBrandOfficial website: https://www.cheerble.com/
DONGGUAN, China and PLANO, Texas, March 25, 2025 /PRNewswire/ -- Dogness (International) Corporation ("Dogness" or the "Company") (NASDAQ: DOGZ), a developer and manufacturer of a comprehensive line of Dogness-branded, OEM and private label pet products, today announced its annual meeting of shareholders for the fiscal year ended June 30, 2024, will be held on March 27, 2025, at 9:00 a.m. China Time (9:00 p.m. Eastern Time on March 26, 2025). The meeting will be held at the Company's executive office at No. 16 N. Dongke Road, Tongsha Industrial Zone, Dongguan, Guangdong, China. The meeting will be held as a hybrid virtual and physical meeting. Shareholders unable to attend in person may attend by call as follows: Topic: DOGNESS (INTERNATIONAL) CORPORATION ANNUAL SHAREHOLDER MEETING 2024 Time: Mar 26, 2025 09:00 PM Eastern Time (US and Canada) Join Zoom Meeting https://us06web.zoom.us/j/88948047162?pwd=Eaypg5PPF1QRRLX59bFAexnam0INbf.1 Meeting ID: 889 4804 7162 Passcode: 916781 Annual meeting materials will be made available on the Company's investor relations website ir.dogness.com and is available in its filings with the U.S. Securities and Exchange Commission on the EDGAR website www.sec.gov. About Dogness Dogness (International) Corporation was founded in 2003 from the belief that dogs and cats are important, well-loved family members. Through its smart products, hygiene products, health and wellness products, and leash products, Dogness' technology simplifies pet lifestyles and enhances the relationship between pets and pet caregivers. The Company ensures industry-leading quality through its fully integrated vertical supply chain and world-class research and development capabilities, which has resulted in over 200 patents and patents pending. Dogness products reach families worldwide through global chain stores and distributors. For more information, please visit: ir.dogness.com. Forward Looking Statements No statement made in this press release should be interpreted as an offer to purchase or sell any security. Such an offer can only be made in accordance with the Securities Act of 1933, as amended, and applicable state securities laws. Certain statements in this press release concerning our future growth prospects are forward-looking statements regarding our future business expectations intended to qualify for the "safe harbor" under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding lingering effects of the Covid-19 pandemic on our customers' businesses and end purchasers' disposable income, our ability to raise capital on any particular terms, fulfillment of customer orders, fluctuations in earnings, fluctuations in foreign exchange rates, our ability to manage growth, our ability to realize revenue from expanded operation and acquired assets in China and the U.S., our ability to attract and retain highly skilled professionals, client concentration, industry segment concentration, reduced demand for technology in our key focus areas, our ability to successfully complete and integrate potential acquisitions, and unauthorized use of our intellectual property and general economic conditions affecting our industry. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings. These filings are available at www.sec.gov. Dogness may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company's filings with the Securities and Exchange Commission and our reports to shareholders. In addition, please note that any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of the date of this press release. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law. For investor and media inquiries, please contact: Wealth Financial Services LLCConnie Kang, PartnerEmail: ckang@wealthfsllc.comTel: +86 1381 185 7742 (CN)
TAIPEI, March 14, 2025 /PRNewswire/ -- Cordyceps Sunshine Biotech Holdings Co., Ltd. 【C.S Group】, in collaboration with the Chinese Herbal Fungi Industry Research and Development Association (CHFIRDA), hosted the "Pharmacological Applications of Taiwanofungus Camphoratus in the Pet Market" Seminar in Taipei. During the event, 【C.S Group】 officially announced its latest research findings, revealing that Antcin A, a purified extract from Taiwanofungus camphoratus, demonstrates potential synergistic effects with traditional steroids. The company is also exploring partnerships with premium pet food brands in China and plans to introduce exclusively supplied Taiwanofungus camphoratus extracts through its Greater China distributor, Guangdong Baoquan Agricultural Biotechnology, as part of its strategy to expand into the high-end pet food market. Accelerating Commercialization of Taiwanofungus Camphoratus-Based Pharmaceuticals Dr. Jia-Xin Huang, a leading expert in Taiwanofungus camphoratus, emphasized that developing new biopharmaceuticals traditionally requires extensive investment in animal and human trials, with no guarantee of success. However, Taiwanofungus camphoratus has already been extensively researched, providing a strong scientific foundation without needing to start from scratch. A key concern in previous discussions has been the long-term use of traditional steroids, which often leads to liver and kidney damage as a side effect. Taiwanofungus camphoratus is known for its liver- and kidney-protective properties, prompting further studies into its potential to reduce the adverse effects of steroids without compromising efficacy. To validate this hypothesis, 【C.S Group】 conducted an experiment combining its proprietary TF-15 Taiwanofungus camphoratus extract with the steroid dexamethasone (DXMS) in lung cancer cell models. The study confirmed: Genetic verification of TF-15 confirmed its authenticity 【C.S Group】as a Taiwanofungus camphoratus strain. TF-15 exhibits comparable potency to wood-cultivated Taiwanofungus camphoratus fruiting bodies. A high concentration of Antcin A was successfully extracted through a multi-stage purification process. The combination of Antcin A and dexamethasone showed potential synergistic effects in reducing and reversing cancer cell growth. Recognizing the regulatory and commercialization advantages of veterinary applications, 【C.S Group】 is prioritizing preclinical trials for pet medicine. The strategy includes: Establishing safe dosage and formulations for pets, such as oral solutions and chewable tablets. Accelerating human clinical trials by leveraging veterinary data. Expanding applications to both pet and human nutraceuticals, providing a flexible market strategy. This approach offers a balanced and strategic entry into the pharmaceutical sector, positioning Taiwanofungus camphoratus as a viable candidate for integrated pet and human health solutions. (Left) C.S Group Chief Technology Officer Vincent Liu; (Right) C.S Group Consultant Dr. Jia-Xin Huang. Pet Health Market Poised for Growth Vincent Liu, Chief Technology Officer at 【C.S Group】, highlighted the significant growth potential in China's pet market. As of 2024, China's pet population reached 124.1 million, with the pet food industry valued at $22.2 billion—including $9.8 billion in cat food and $10.3 billion in dog food. While mature markets like North America and Europe have penetration rates exceeding 90%, China's market penetration is still around 20%, signaling substantial room for growth. According to the China Feed Industry Association (CFIA), there are approximately 200 certified pet food manufacturers in China, with a total annual production capacity of 1.12 million tons. The market is shifting towards premium branding, creating opportunities for high-end functional pet foods. 【C.S Group】 is actively engaging with China's leading premium pet food brands and, through its Greater China distributor, Guangdong Baoquan Agricultural Biotechnology, plans to integrate Taiwanofungus camphoratus extracts into premium pet food formulations. Beyond pet nutrition, veterinary pharmaceuticals present another growth avenue. The global pet pharmaceutical market includes treatments for external and internal parasites, allergic dermatitis, anti-inflammatory pain relief, anti-nausea, insulin, antibiotics, and heart failure management. Given the broad-spectrum bioactivity of Taiwanofungus camphoratus, its potential therapeutic applications in pet medicine are highly promising. Leading the Market with Antcin A Mass Production Dalan Huang, President of 【C.S Group】, emphasized the importance of high-quality cultivation in ensuring premium product yields. He highlighted the company's commitment to optimizing Taiwanofungus camphoratus strain selection and mass production, enabling efficient extraction and purification of bioactive compounds for pharmaceutical applications. "The efficacy of Antcin A is well established in the industry, but the real question is: who has the capability to lead the market in large-scale extraction and production?" Huang stated. "Whoever masters the mass production of Taiwanofungus camphoratus extracts will control the next phase of the industry." While the company has ambitious goals, Huang stressed the importance of achievable milestones. Based on Dr. Jia-Xin Huang's preliminary findings, 【C.S Group】 has already made exciting progress and is optimistic that further optimization will lead to the development of the first batch of Taiwanofungus camphoratus-based veterinary pharmaceuticals. This breakthrough has the potential to accelerate commercialization and integration into the pet health industry. With scientific validation, strategic partnerships, and market positioning, 【C.S Group】 is advancing Taiwanofungus camphoratus from traditional applications to next-generation pharmaceuticals. As the global pet and human health industries continue to expand, the company is well-positioned to lead innovation in functional ingredients and biopharmaceutical applications.
New studies reveal that the three-strain Bacillus probiotic can better protect weaned piglets against diverse health challenges. SINGAPORE, March 11, 2025 /PRNewswire/ -- IFF (NYSE:IFF) today announced the extension of their three-strain Bacillus probiotic, Enviva® PRO, to pigs. By incorporating IFF's probiotic into their diet, producers will be better positioned to protect their animals against diverse health challenges. The extension of Enviva® PRO enhances IFF's robust portfolio of proven, cost-effective animal nutrition and health solutions that help customers optimize production, livability and profitability. "The weaning and post-weaning period can be extremely difficult to navigate for swine producers, so implementing a nutritional management strategy is crucial for improving their welfare and avoiding growth setbacks," said Dr. Ester Vinyeta, swine innovation lead at IFF. "In addition to the proven benefits of Enviva® PRO already experienced by broiler producers, swine producers now can have peace of mind that their litters have optimal gut health – helping them meet growing production demands." Post-weaning, piglets may face challenges like nutritional stress, reduced feed intake, and digestive health issues, which can impact performance. Enviva® PRO is proven to establish and maintain a favorable nutribiotic state that supports optimal gut function, leading to improved nutrient digestion and performance. Extensive studies performed by IFF found that compared to the control group, Enviva® PRO improved average daily weight gain by 2.5% and reduced diarrhea frequency by 6.3%. Enviva® PRO is currently available to swine producers across Japan and the US. IFF plans to extend availability to other territories following pending regulatory authorizations. Learn more about the benefits of Enviva® PRO and nutribiosis in animal production at animalnutrition.iff.com/enviva-pro. About Danisco Animal Nutrition & Health Danisco Animal Nutrition & Health, part of IFF, is an industry leader in nutritional health solutions with a comprehensive portfolio of feed enzymes, betaine, essential oils and probiotics. Through the lens of nutribiosis, IFF invests in science and innovation to help producers improve performance, increase liveability and support welfare in the face of increasing pressure to reduce or remove antibiotics from production systems. Danisco Animal Nutrition & Health capabilities are underpinned by the quality and quantity of our trials, including over 100,000 guts sampled from over 600 farms, investments in omics technologies and microbiome research, and collaboration with leading commercial, governmental and academic partners. For more information, visit iff.com/animal-nutrition. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. ©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.
Animals/Pets
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
